Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 2.300

+0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Nobrega who started this subject	9/7/2003 2:12:43 PM
From: PL Wilson	of 1870

GENTA presenting at Fall 2003 NCI CTEP Drug Development Meeting 9/08/03 4:00 p.m. G3139—Introduction James A. Zwiebel, M.D. Investigational Drug Branch National Cancer Institute 4:05 p.m. G3139 Studies in Combination with Chemotherapy Anthony W. Tolcher, M.D. Institute for Drug Development 4:25 p.m. Phase II Study of Genasense in Combination with Thalidomide and Dexamethasone in Multiple Myeloma Ashraf Badros, M.D. University of Maryland 4:40 p.m. G3139 Plus Daunorubicin and Cytarabine in Untreated AML in the Elderly Guido Marcucci, M.D. Ohio State University palladianpartners.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next